enable the discovery and identification of lead candidates. AdAlta can rapidly identify high quality binders from it's i-body or shark antibody libraries.

A particular focus is given to the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane spanning proteins. AdAlta’s proprietary discovery technology is particularly well suited to approach this class of drug-targets that formerly was inaccessible to most protein-binder platforms.

AdAlta is focused on building a pipeline of therapeutics against clinically validated targets that demonstrate significant advantages over currently marketed protein products.

AdAlta also conducts collaborative and contract research. Our approach allows us to leverage the diversity of the AdAlta libraries and apply it to collaborators targets. AdAlta has a number of collaborations with research organization, biotech and pharma companies.